AstraZeneca said a late-stage trial had confirmed the benefit of breast cancer drug Enhertu in patients with an advanced form of the disease who had been previously treated with another therapy.
If you are not happy with the results below please do another search
50 search results for:
As the biotech world awaits the announcement of Merck’s anticipated buyout of Seagen, an arbitrator came down on the side of Daiichi Sankyo in a patent battle against the Seattle-based biotech.
On Monday, Novartis released results from the Phase III CANOPY-A trial, showing that its candidate canakinumab (ACZ885) failed to meet its primary efficacy endpoint in adult non-small cell lung cancer (NSCLC) patients.
In what has been a long time coming, Tel Aviv and New York-based BrainStorm announced Monday that it would submit a Biologics License Application (BLA) to the FDA for NurOwn as a potential treatment for ALS. Simultaneously, BrainStorm announced corrected analyses it says strengthen its original conclusions.
Novavax Inc. said on Monday it had filed for U.S. authorization for use of its COVID-19 vaccine as a booster dose in people who had either received its shots or a different vaccine.
UK’s Joint Committee on Vaccination and Immunisation agency will now decide how shot should be deployed. In addition Moderna anticipates Australia, Canada, and EU approvals soon.
Technology has transformed the industry, significantly expanding pharma pipelines, facilitating more engagement, and empowering patients.
The labor market has been forever changed by COVID-19. However, the changes in recruiting and retaining talent in pharma marketing and advertising started well before the pandemic. The traditional, linear career development path is not necessarily standard anymore, and the industry is looking in a variety of areas for talented professionals. MedAdNews asked several of its editorial advisory board members to reflect and weigh in on how the talent pool has changed over the years.
Drugmakers are launching new medicines at record-high prices this year, a Reuters analysis has found, highlighting their pricing power even as Congress moves to cut the $500 billion-plus annual bill for prescription drugs in the United States.
For our 40th Anniversary Edition, we asked our editorial advisory board members to talk about the most significant strides they’ve seen over the course of their careers, how client challenges have changed, thoughts on talent and recruitment strategies, and trends that are advancing the industry. Obviously one of the biggest changes has been the role of digital technology and its part in personalization. But frankly, we barely scratched the surface!